Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
Breast Cancer Index® (BCI)
- Molecular
NeoGenomics has partnered with Biotheranostics, a Hologic Company, to make ordering BCI easy for women with early-stage hormone receptor-positive (HR+) breast cancer. BCI is the only test recognized by the NCCN® Guidelines to predict which patients are likely to benefit from extended adjuvant anti-estrogen therapy beyond 5 years.
Level of Service
- Global
New York Approved: Yes
Specimen Requirements
Testing is performed on breast primary invasive tumor. FFPE tissue: Paraffin block is preferred. Alternatively, send 3-4 unstained, 10 micron thick sections on glass slides (an area of tumor that contains ≥40% neoplastic cells) and one H&E-stained slide. Note: Cases with the following clinical or specimen characteristics are not acceptable: post-treatment (adjuvant or neoadjuvant) specimens, fine needle aspirations (FNA), fresh or frozen tissue, both ER- and PR-, positive nodes, microinvasive carcinoma, metaplastic or metastatic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, phyllodes tumor, male gender, T4 tumor, no evidence of invasive (ductal, lobular or mixed ductal lobular) carcinoma, biopsy site of chest wall, skin, axilla or lymph node.
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.
CPT Code(s)*
Please contact Biotheranostics, Inc. at 877-886-6739.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: April 03, 2025